Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products that include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. It also provides spinal implant products comprising cervical, thoracolumbar, and interbody systems for use in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned sales subsidiaries and branches, as well as third-party dealers and distributors in approximately 85 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:SYK
CUSIP86366710
Phone269-389-2600
Debt
Debt-to-Equity Ratio0.63
Current Ratio1.83
Quick Ratio1.15
Price-To-Earnings
Trailing P/E Ratio26.05
Forward P/E Ratio23.33
P/E Growth2.35
Sales & Book Value
Annual Sales$12.44 billion
Price / Sales5.08
Cash Flow$8.4660 per share
Price / Cash19.98
Book Value$26.67 per share
Price / Book6.34
Profitability
EPS (Most Recent Fiscal Year)$6.49
Net Income$1.02 billion
Net Margins8.28%
Return on Equity26.93%
Return on Assets12.05%
Miscellaneous
Employees33,000
Outstanding Shares373,990,000
Market Cap$62.04 billion
Stryker (NYSE:SYK) Frequently Asked Questions
What is Stryker's stock symbol?
Stryker trades on the New York Stock Exchange (NYSE) under the ticker symbol "SYK."
How often does Stryker pay dividends? What is the dividend yield for Stryker?
Stryker declared a quarterly dividend on Thursday, May 3rd. Stockholders of record on Friday, June 29th will be given a dividend of $0.47 per share on Tuesday, July 31st. This represents a $1.88 dividend on an annualized basis and a dividend yield of 1.11%. The ex-dividend date of this dividend is Thursday, June 28th. View Stryker's Dividend History.
How were Stryker's earnings last quarter?
Stryker Co. (NYSE:SYK) released its earnings results on Tuesday, July, 24th. The medical technology company reported $1.76 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $1.73 by $0.03. The medical technology company had revenue of $3.32 billion for the quarter, compared to analyst estimates of $3.31 billion. Stryker had a net margin of 8.28% and a return on equity of 26.93%. The company's quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the company earned $1.53 earnings per share. View Stryker's Earnings History.
When is Stryker's next earnings date?
What guidance has Stryker issued on next quarter's earnings?
Stryker issued an update on its FY18 earnings guidance on Tuesday, July, 24th. The company provided earnings per share guidance of $7.22-7.27 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.23. Stryker also updated its Q3 guidance to $1.65-1.70 EPS.
What price target have analysts set for SYK?
23 equities research analysts have issued 12-month target prices for Stryker's stock. Their predictions range from $148.00 to $192.00. On average, they expect Stryker's stock price to reach $175.95 in the next twelve months. This suggests a possible upside of 3.9% from the stock's current price. View Analyst Price Targets for Stryker.
What is the consensus analysts' recommendation for Stryker?
23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stryker in the last year. There are currently 1 sell rating, 7 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Stryker.
What are Wall Street analysts saying about Stryker stock?
Here are some recent quotes from research analysts about Stryker stock:
- 1. According to Zacks Investment Research, "Stryker wrapped up the second quarter on a solid note, with earnings and revenues beating estimates. The company continues to gain from its flagship Mako Total Knee platform, which drove its core Orthopaedic segment. In fact, Mako saw increasing robot installations in the quarter. Surging domestic sales is a positive. Moreover, solid performance in emerging markets and Europe paints a bright picture. Considerable expansion in operating margin is encouraging as well. Higher R&D expenses indicate increasing focus on innovation. However, Stryker’s Spine business continued to see market softness and mid-single digit pricing declines. Further, supply issues in the Puerto Rico facility continue to plague the company. The slowdown of MedSurg’s sustainability revenue growth is another negative. Stiff competition is likely to mar Stryker’s prospects. Stryker underperformed the industry in a year." (8/8/2018)
- 2. Needham & Company LLC analysts commented, "SYK’s 2Q18 revenue met consensus while its EPS beat consensus. Management raised its 2018 organic revenue growth and EPS guidance. Adjusting for selling days (+1 in 2Q18 and -1 in 1Q18), organic growth slowed to 6.9% in 2Q18 from 8.0% in 1Q18. SYK placed 39 Mako systems in 2Q18 and over 40% of placements were in competitive accounts. SYK’s operating margin was above consensus and was up 50 bps Y/Y adjusted for ASC 606. Given SYK’s top and bottom line growth profiles, we believe SYK shares are fairly valued (23.8x vs. large cap ortho peers at 19.0x) and we maintain our Hold rating." (7/25/2018)
- 3. Cantor Fitzgerald analysts commented, ". This morning (6/11), Journal reported that SYK made a takeover approach of Boston Scientific (Not Covered). Trading on both stocks was halted for a period of time during the day. BSX released an 8-K saying that it was aware of the story, but in accordance with company practice, it does not comment on market rumors or speculation. SYK made similar comment when we reached out directly to them. We view SYK’s potential interest positively, although as somewhat unexpected." (6/13/2018)
Who are some of Stryker's key competitors?
Some companies that are related to Stryker include 3M (MMM), Becton Dickinson and (BDX), Boston Scientific (BSX), FRESENIUS SE &/S (FSNUY), Baxter International (BAX), ABIOMED (ABMD), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hill-Rom (HRC), ICU Medical (ICUI), Integra Lifesciences (IART), Haemonetics (HAE), Globus Medical (GMED) and Insulet (PODD).
Who are Stryker's key executives?
Stryker's management team includes the folowing people:
- Mr. Kevin A. Lobo, Chairman & CEO (Age 53)
- Mr. Timothy J. Scannell, Pres & COO (Age 53)
- Mr. Glenn S. Boehnlein, VP & CFO (Age 56)
- Mr. Lonny J. Carpenter, Group Pres & Adviser to the CEO (Age 56)
- Mr. David K. Floyd, Group Pres & Advisor to the CEO (Age 57)
Has Stryker been receiving favorable news coverage?
Media coverage about SYK stock has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Stryker earned a media and rumor sentiment score of 0.05 on Accern's scale. They also assigned press coverage about the medical technology company an impact score of 45.68 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days. View Recent Headlines for Stryker.
Who are Stryker's major shareholders?
Stryker's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.56%), Greenleaf Trust (6.17%), Massachusetts Financial Services Co. MA (2.25%), Bank of New York Mellon Corp (2.13%), FMR LLC (1.42%) and Morgan Stanley (0.62%). Company insiders that own Stryker stock include David Floyd, Glenn S Boehnlein, Graham A Mclean, Howard E Cox Jr, Katherine Ann Owen, Kevin Lobo, Lonny J Carpenter, Louise Francesconi, M Kathryn Fink, Roch Doliveux, Ronda E Stryker, Timothy J Scannell, William E Berry Jr and Yin C Becker. View Institutional Ownership Trends for Stryker.
Which major investors are selling Stryker stock?
SYK stock was sold by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., Bank of New York Mellon Corp, Yacktman Asset Management LP, Jensen Investment Management Inc., Greenleaf Trust, CIBC Private Wealth Group LLC, Russell Investments Group Ltd. and Janus Henderson Group PLC. Company insiders that have sold Stryker company stock in the last year include David Floyd, Glenn S Boehnlein, Graham A Mclean, Howard E Cox Jr, Katherine Ann Owen, Kevin Lobo, Lonny J Carpenter, M Kathryn Fink, William E Berry Jr and Yin C Becker. View Insider Buying and Selling for Stryker.
Which major investors are buying Stryker stock?
SYK stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Point72 Asset Management L.P., BlackRock Inc., Bank of America Corp DE, California Public Employees Retirement System, Morgan Stanley, Advisors Asset Management Inc. and British Airways Pensions Investment Management Ltd. View Insider Buying and Selling for Stryker.
How do I buy shares of Stryker?
Shares of SYK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Stryker's stock price today?
One share of SYK stock can currently be purchased for approximately $169.38.
How big of a company is Stryker?
Stryker has a market capitalization of $62.04 billion and generates $12.44 billion in revenue each year. The medical technology company earns $1.02 billion in net income (profit) each year or $6.49 on an earnings per share basis. Stryker employs 33,000 workers across the globe.
How can I contact Stryker?
Stryker's mailing address is 2825 AIRVIEW BLVD, KALAMAZOO MI, 49002. The medical technology company can be reached via phone at 269-389-2600 or via email at [email protected]
MarketBeat Community Rating for Stryker (NYSE SYK)
MarketBeat's community ratings are surveys of what our community members think about Stryker and other stocks. Vote "Outperform" if you believe SYK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYK will underperform the S&P 500 over the long term. You may vote once every thirty days.
